At a glance
ClinicalIndex Comparison Record- ✓Age 60 or older
- ✓Amnestic mild cognitive impairment (single or mixed domain) or mild Alzheimer's disease with CDR 0.5-1, OR cognitively unimpaired with CDR 0
- ✓Able to tolerate MRI and PET scanner procedures including venous access
- ✕History of brain disorders other than MCI or Alzheimer's disease
- ✕Significant medical conditions making study procedures unsafe
- ✕Contraindication to MRI scanning
- ✕Conditions precluding scanner entry (morbid obesity, claustrophobia, etc.)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Imaging Inflammation in Elders With Different Clinical and Biomarker Profiles of Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating 11C-PBR28, 18F-Florbetaben, and 1 other intervention for Alzheimer's Disease. Completed, enrolled 60 participants across 1 site.
Detailed Summary
This study is being done to learn about inflammation and amyloid in Alzheimer's disease. A type of brain scan called a PET scan is used measure 1) inflammation and 2) abnormal accumulation of a the amount of a certain protein fragment called beta-amyloid (plaques) in the brain. These are thought to be involved in Alzheimer's disease. The investigators will also perform brain MRI and do tests to measure the participants' memory and thinking.
Study Details
Timeline
Interventions
11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.
18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.
Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.